IDHC vs. GDR, LLAI, EVG, N4P, DEMG, PYC, APTA, NFX, IQAI, and HELD
Should you be buying Integrated Diagnostics stock or one of its competitors? The main competitors of Integrated Diagnostics include genedrive (GDR), LungLife AI (LLAI), Evgen Pharma (EVG), N4 Pharma (N4P), Deltex Medical Group (DEMG), Physiomics (PYC), Aptamer Group (APTA), Nuformix (NFX), IQ-AI (IQAI), and Hellenic Dynamics (HELD). These companies are all part of the "medical" sector.
Integrated Diagnostics (LON:IDHC) and genedrive (LON:GDR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends, profitability and community ranking.
genedrive received 186 more outperform votes than Integrated Diagnostics when rated by MarketBeat users. Likewise, 72.67% of users gave genedrive an outperform vote while only 65.12% of users gave Integrated Diagnostics an outperform vote.
In the previous week, genedrive had 2 more articles in the media than Integrated Diagnostics. MarketBeat recorded 2 mentions for genedrive and 0 mentions for Integrated Diagnostics. genedrive's average media sentiment score of 0.69 beat Integrated Diagnostics' score of 0.00 indicating that genedrive is being referred to more favorably in the news media.
Integrated Diagnostics has higher revenue and earnings than genedrive. genedrive is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.
39.3% of Integrated Diagnostics shares are owned by institutional investors. Comparatively, 1.2% of genedrive shares are owned by institutional investors. 27.1% of Integrated Diagnostics shares are owned by company insiders. Comparatively, 39.6% of genedrive shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Integrated Diagnostics has a net margin of 13.96% compared to genedrive's net margin of 0.00%. Integrated Diagnostics' return on equity of 19.69% beat genedrive's return on equity.
Integrated Diagnostics has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, genedrive has a beta of 0.18, meaning that its stock price is 82% less volatile than the S&P 500.
Summary
Integrated Diagnostics beats genedrive on 9 of the 15 factors compared between the two stocks.
Get Integrated Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IDHC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Integrated Diagnostics Competitors List
Related Companies and Tools